Navigation Links
Hospira Expands Board of Directors
Date:8/17/2011

LAKE FOREST, Ill., Aug. 17, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced that William G. Dempsey has been elected to the company's board of directors. Dempsey brings strong executive management and diverse global experience from leadership positions held in the healthcare industry. The addition of Dempsey expands Hospira's board to 11 directors, nine of whom are independent.

(Logo:  http://photos.prnewswire.com/prnh/20040503/HSPLOGO)

"Bill understands how to successfully grow a large, multinational healthcare business," said Christopher B. Begley, executive chairman. "His impressive track record of results-oriented leadership and operational experience in the healthcare field makes him an excellent fit for the Hospira board."

John C. Staley, Hospira's lead director, added, "We are excited to welcome Bill to Hospira's board of directors. His broad and deep knowledge of global healthcare markets enhances our current board membership and supports Hospira's goals for international expansion."

Dempsey, 59, spent more than two decades at Abbott Laboratories, most recently serving as executive vice president, Global Pharmaceuticals, where he was responsible for the company's $14 billion global pharmaceutical business, representing more than 33,000 employees. In this position, from which he retired in 2007, he drove the business to 15 percent growth in revenues and profitability in the face of major new generic competition. He also led an initiative that doubled research and development productivity over three years, and negotiated and integrated the successful $3.7 billion acquisition of the cardiovascular company, Kos Pharmaceuticals.

From 2003 to 2006, Dempsey was Abbott's senior vice president, Pharmaceutical Operations, responsible for Abbott's $8 billion U.S. pharmaceuticals business. In this role, Dempsey consistently delivered strong sales growth and successfully launched the blockbuster rheumatoid arthritis drug Humira.

Previously, Dempsey was Abbott's senior vice president, International Operations, where he served from 1999 to 2003, managing all of Abbott's pharmaceutical, hospital and nutritional businesses outside the United States. During his tenure, he grew the business from approximately $3 billion in sales to $5 billion in sales.

In prior roles at Abbott, Dempsey served as senior vice president, Chemical and Agricultural Products, and vice president, Hospital Products Business Sector, among other positions. Before working at Abbott, Dempsey served in various roles at Sciaky Brothers Inc. and Crane Company.

Dempsey currently serves on the boards of Landauer, Inc. and Nordion, Inc. A native of Chicago, Ill., he holds a Bachelor of Science degree from DePaul University.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
2. Hospira Reports Second-Quarter 2011 Results
3. Hospira to Host Conference Call for Second-Quarter 2011 Results
4. Hospira Receives Health Canada Regulatory Approval for Symbiqâ„¢ Infusion System Software Upgrade
5. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
6. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
7. Hospira Reports First-Quarter 2011 Results
8. Hospira Board Authorizes $1 Billion Share Repurchase Program
9. Hospira to Present at Bank of America / Merrill Lynch 2011 Health Care Conference May 11, 2011
10. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
11. Hospira to Host Conference Call for First-Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):